Blood Tests Before Starting a GLP-1 Program

One of the most important steps before starting a GLP-1 program is one that many people skip entirely: comprehensive baseline blood work. Without it, you are starting a powerful metabolic intervention without knowing your starting point, and without the safety information a physician needs to prescribe appropriately.

At Longegra, baseline biomarker testing is not optional. It is the foundation of every GLP-1 program.

Why Baseline Blood Tests Matter

Baseline testing serves three purposes:

1. Safety screening: Certain conditions, including active pancreatitis, severe kidney disease, and specific thyroid disorders, are relative or absolute contraindications to GLP-1 therapy. Lab work identifies these before you begin.
2. Personalisation: Your fasting glucose, HbA1c, insulin levels, and lipid profile determine which peptide and which starting dose are most appropriate for your physiology.
3. Progress tracking: Without a baseline, you cannot measure how much your metabolic health has improved. Numbers on a re-test six months in are meaningless without a starting point.

The Essential Pre-GLP-1 Panel

Glycaemic Markers

• Fasting glucose: Establishes your baseline blood sugar and identifies pre-diabetes or diabetes
• HbA1c: Reflects average blood sugar over the past 90 days; essential for dosing decisions and tracking long-term glycaemic improvement
• Fasting insulin: Identifies insulin resistance even when fasting glucose is still normal; the most sensitive early marker of metabolic dysfunction

Lipid Panel

• Total cholesterol, LDL, HDL, and triglycerides: GLP-1 improves all four markers, but knowing your baseline tells you how much improvement is needed and tracks cardiovascular risk reduction over time

Liver Function

• ALT, AST, and GGT: GLP-1 can affect liver enzyme levels, and elevated baseline enzymes may indicate underlying fatty liver disease, relevant both for safety and for tracking therapeutic benefit

Kidney Function

• Creatinine and eGFR: Essential for safety screening, as GLP-1 dosing considerations apply to patients with impaired kidney function

Thyroid Function

• TSH (thyroid-stimulating hormone): Hypothyroidism is a common undiagnosed cause of weight gain and metabolic resistance that can significantly blunt GLP-1 response

Inflammation Markers

• CRP (C-reactive protein): A marker of systemic inflammation linked to visceral fat; tracking its reduction over the course of GLP-1 therapy confirms anti-inflammatory benefit

Hormone Panel (Especially for Men)

For male patients, Longegra includes a hormone panel as part of the pre-GLP-1 workup:

• Total and free testosterone: Visceral fat suppresses testosterone via aromatase activity; baseline testing identifies whether testosterone optimisation is needed alongside GLP-1 therapy
• SHBG (sex hormone-binding globulin): Elevated SHBG reduces bioavailable testosterone; important for interpreting total testosterone in context
• Oestradiol: Relevant for men with significant visceral fat, as aromatase converts testosterone to oestradiol

What the Results Tell You

Your lab results do more than confirm safety. They reveal the specific metabolic levers GLP-1 therapy will address:

• High fasting insulin with normal fasting glucose = early insulin resistance, where GLP-1 will have meaningful preventive benefit
• Elevated triglycerides and low HDL = atherogenic dyslipidaemia pattern most dramatically improved by GLP-1
• Elevated ALT/AST = possible non-alcoholic fatty liver disease, a condition GLP-1 has demonstrated specific benefit for
• Suppressed testosterone in men = metabolic driver that GLP-1 may partially reverse through visceral fat reduction

These patterns shape the clinical conversation and the protocol.

Retesting During Your Program

Baseline tests are only the starting point. At Longegra, we re-test key markers at three months and six months to:

• Confirm metabolic improvement is occurring as expected
• Identify any emerging safety signals early
• Adjust your protocol based on what the numbers show, not just how you feel

This approach to data-driven treatment is one of the core differentiators between a Longegra program and an unsupervised approach.